Search Results - michael+wempe

4 Results

Sort By:

Urate Transport Inhibitors: Compounds Designed for Their Uricosuric Action

Heightened urate levels are prevalent in a variety of disease states, including gout, hypertension, diabetes, and cardiovascular disease. Currently, there are few drugs approved in the USA for the lowering of blood urate levels. Among those marketed, many either have extreme unintended maladies, like Stevens Johnson syndrome, require frequent dosing,...

Published: 5/25/2023 | Inventor(s): Michael Wempe, Hitoshi Endou

Disease Areas Nephrology

Category(s): Therapeutics

Diagnostic Markers for Pyridoxine Dependent Epilepsy

Pyridoxine dependent epilepsy (PDE) is a rare genetic disorder characterized by intractable seizures in the prenatal and neonatal period. Approximately, 75% of those diagnosed suffer from intellectual disability and developmental delay. Although effective treatments exist, therapeutics must be administered quickly and current diagnosis procedures are...

Published: 8/29/2022 | Inventor(s): Curtis Coughlin II, Michael Wempe, Johan Van Hove

Disease Areas Neurology

Category(s): Diagnostics

Novel Compounds Targeting RNA Polymerase Binding Transcription Factor DksA for Treatment of Drug-Resistant Gram-Negative Infections

Scientists at the University of Colorado and National Jewish Health have identified novel compounds that specifically inhibit DksA activity in Gram-negative bacteria. Drugs against DksA have antibiotic activity against several Gram-negative pathogens. Moreover, the newly discovered drugs act against persistent populations of intracellular bacteria and...

Published: 5/26/2023 | Inventor(s): Michael Wempe, Andres Vazquez-Torres, Shaodong Dai

Disease Areas Infectious Disease

Category(s): Therapeutics

Derivatives of the small molecule anticancer drug, AMPI-109

Triple-negative breast cancer (TNBC) does not express the estrogen, progesterone or HER2 receptors and accounts for 10-20% of all breast cancer cases. TNBC lacks exploitable targets and tends to be higher grade than other breast cancers, making it difficult to develop effective treatments. PRL-3 is an oncogenic phosphatase that is overexpressed in many...

Published: 5/9/2023 | Inventor(s): James Lambert, Michael Wempe, M. Scott Lucia, Rahul Ray

Disease Areas Oncology

Category(s): Therapeutics